20/20 Biolabs, Inc.
AIDX Nasdaq Services-Testing Laboratories Financials FY2024–FY2025
What 20/20 Biolabs, Inc. does
No business description yet.
- Legal name
- 20/20 Biolabs, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001213900-26-037667
0001139685
Revenue and margins
20/20 Biolabs, Inc. had $2.0M of revenue in fiscal 2025, up 16.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
20/20 Biolabs, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 2.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably 20/20 Biolabs, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $1.8M | $1.0M |
| Interest coverage | −450.6x | −21.3x |
| Current ratio | 1.5x | 0.6x |
| Quick ratio | 1.5x | 0.6x |
| Total assets | $3.6M | $4.1M |
| Total liabilities | $2.1M | $4.2M |
| Shareholders' equity | $1.5M | −$0.0M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | ✓ |
| Revenue rose relative to assets | — | ✓ |
| F-score | — / 3 | 4 / 8 |
| Accruals ratio | −82.4% | −47.1% |
| Altman Z'' | −35.48 | −33.18 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $1.8M | $2.0M |
| Gross profit | $0.4M | $0.6M |
| Research and development | $1.3M | $0.6M |
| Operating income | −$5.7M | −$3.3M |
| Interest expense | $0.0M | $0.2M |
| Net income | −$5.6M | −$3.7M |
| Diluted EPS | −$1.16 | −$0.76 |
| Diluted shares | 0.00B | 0.00B |
| Cash flow | ||
| Cash from operations | −$2.6M | −$1.9M |
| Depreciation and amortization | $0.1M | $0.1M |
| Stock-based compensation | $2.2M | $0.5M |
| Balance sheet | ||
| Cash and short-term investments | $1.8M | $1.0M |
| Current assets | $2.0M | $1.5M |
| Current liabilities | $1.4M | $2.5M |
| Inventory | $0.0M | $0.1M |
| Property and equipment, net | $0.1M | $0.1M |
| Intangible assets | $0.2M | $0.2M |
| Total assets | $3.6M | $4.1M |
| Total liabilities | $2.1M | $4.2M |
| Shareholders' equity | $1.5M | −$0.0M |
| Margins | ||
| Gross margin | 20.6% | 29.6% |
| Operating margin | −324.0% | −162.9% |
| EBITDA margin | −317.4% | −159.8% |
| Net margin | −316.8% | −182.8% |
| Returns | ||
| Return on capital employed | −254.7% | −198.9% |
| Return on equity | −368.8% | −503.1% |
| Return on assets | −154.9% | −96.8% |
| Return on tangible equity | −427.1% | — |
| Growth | ||
| Revenue growth | — | 16.7% |
| Share count change | — | 2.7% |
| Financial health | ||
| Interest coverage | −450.6x | −21.3x |
| Current ratio | 1.5x | 0.6x |
| Quick ratio | 1.5x | 0.6x |
| Capital allocation | ||
| Stock comp / revenue | 124.2% | 25.2% |
| Quality scores | ||
| Piotroski F-score | — | 4.0 |
| Altman Z'' | −35.5 | −33.2 |
| Accruals ratio | −82.4% | −47.1% |
Source: SEC EDGAR XBRL filings (CIK 0001139685). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.